Cutaneous manifestations of Taxol therapy

• Published in: Investigational new drugs Vol. 13; no. 3; p. 261
• Main Authors: Link, Jr, C J, Sarosy, G A, Kohn, E C, Christian, M C, Davis, P, Adamo, D O, Reed, E
• Format: Journal Article
• Language: English
• Published: United States 01.01.1995
• Subjects: Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Dermatitis, Contact - etiology; Drug Therapy, Combination; Extravasation of Diagnostic and Therapeutic Materials - complications; Female; Granulocyte Colony-Stimulating Factor - drug effects; Humans; Middle Aged; Nail Diseases - chemically induced; Neoplasm Staging; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Paclitaxel - adverse effects; Paclitaxel - therapeutic use
• ISSN: 0167-6997
• DOI: 10.1007/BF00873811

Taxol is a novel chemotherapeutic agent that has produced substantial responses in early clinical studies [1]. Taxol has excellent activity in a number of malignancies based on recently completed clinical trials, including a 30% response rate in platinum-refractory ovarian cancer patients [2-5]. We are currently conducting trials of dose-intense taxol with granulocyte colony stimulating factor (G-CSF) support in relapsed or refractory ovarian cancer patients. Such dose intensification produces a major response rate in 50% of patients with this disease [6]. Taxol was supplied in 5 ml ampules (6 mg/ml) in polyethoxylated castor oil (Cremophor EL) 50% and dehydrated alcohol and the dose was diluted in either 0.9% sodium chloride or 5% dextrose at concentrations of 0.6 to 1.2 mg/ml. We have noted 3 patients with previously unreported cutaneous manifestations which we believe are taxol related and also report our overall complication rate with the administration of taxol by peripheral intravenous lines.